Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer
Erin Dickman MS, RN, OCN®
Voice
Description
The U.S. Food and Drug Administration (FDA) first approved atezolizumab (Tecentriq®) in 2016, but it received additional approvals when used in combination treatments for locally advanced or metastatic triple negative breast cancer (TNBC) and small cell lung cancer (SCLC) in March 2019.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education